enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. New weight loss drug retatrutide shows promise in trial ... - AOL

   www.aol.com/weight-loss-drug-retatrutide-shows...

   More than half of the world population will be obese by 2035, according to the 2023 World Obesity Atlas.. Obesity-related conditions include heart disease, stroke, certain cancers, and type 2 ...

3. Health Rounds: Next generation Lilly weight-loss drug shows ...

   www.aol.com/news/health-rounds-next-generation...

   At 48 weeks, for example, retatrutide had reduced levels of triglycerides by up to 40.6%, and levels of a protein called apoC-III involved in glucose metabolism and inflammation by 38%.

4. Experimental Weight-Loss Drug Retatrutide May Be More ... - AOL

   www.aol.com/lifestyle/experimental-weight-loss...

   Eli Lily’s weight-loss drug retatrutide helped patients lose 24% of their body weight, new data shows. The results rivaled Ozempic. Experts share what to know.

5. Retatrutide - Wikipedia

   en.wikipedia.org/wiki/Retatrutide

   Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist ( GLP-1 , GIP , and GCGR receptors). [ 1 ]

6. Anti-obesity medication - Wikipedia

   en.wikipedia.org/wiki/Anti-obesity_medication

   Weight loss drugs have been developed since the early twentieth century, and many have been banned or withdrawn from the market due to adverse effects, including deaths; other drugs proved ineffective. Although many earlier drugs were stimulants such as amphetamines, in the early 2020s, GLP-1 receptor agonists became popular for weight loss.

7. Consumer Reports - Wikipedia

   en.wikipedia.org/wiki/Consumer_Reports

   Consumer Reports (CR), formerly Consumers Union (CU), is an American nonprofit consumer organization dedicated to independent product testing, investigative journalism, consumer-oriented research, public education, and consumer advocacy.